Development Royalty Sample Clauses

Development Royalty. Sumo shall pay to PowerStream a royalty of seventy-five cents per unit that contains the Licensed Product for which Sumo has collected payment for during a given calendar quarter. 4.

Development Royalty. In consideration of the rights and licenses granted hereunder, the Partnership shall pay, or shall cause to be paid, for the term of this Agreement, as a development royalty (the “Development Royalty”) to [*], an amount equal to [*] of Net Sales of Clopidogrel Products in Territory B.

Development Royalty. In consideration of the rights and licenses granted hereunder, the Licensee shall pay, or shall cause to be paid, for the term of this Agreement the following aggregate amounts as a development royalty (each a “Development Royalty”), provided that, with respect to BMS, such royalty payments shall cease as of December 31, 2018 and the licenses granted by BMS to the Licensee under this Agreement shall become [*] and [*] as of such date: (i) To [*], an amount equal to [*] of IFRS Net Sales of Irbesartan Products in Territory B1; and (ii) To [*], an amount equal to [*] of IFRS Net Sales of Clopidogrel Products in Territory B1.

Development Royalty. In consideration of the rights and licenses granted hereunder, the Partnership shall pay, or shall cause to be paid, for the term of this Agreement the following aggregate amounts as a development royalty (each a “Development Royalty”): (i) To [*], an amount equal to [*]of Net Sales of Irbesartan Products in Territory B; and (ii) To [*], an amount based on Net Sales of Clopidogrel Products in Territory B, which shall be determined by [*] no later than sixty (60) days after the first commercial sale of any Clopidogrel Product in Territory B. * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

Development Royalty. In consideration of the rights and licenses granted hereunder, the SNC Partnership shall pay, or shall cause to be paid, for the term of this Agreement the following aggregate amounts as a development royalty (each a “Development Royalty”), provided that, with respect to BMS, such royalty payments shall cease as of December 31, 2018 and the license granted by BMS to the SNC Partnership under this Agreement shall become [*] and [*] as of such date: (i) To each of Sanofi and BMS, an amount equal to [*] of IFRS Net Sales of Irbesartan Products in Territory A; and (ii) To each of Sanofi and BMS, an amount equal to [*] of IFRS Net Sales of Clopidogrel Products in Territory A.